MVision AI arkistot | MVision AI

Refining Volumes – a Study on Cardiac Substructures’ Impact on Survival in Lung Cancer Patients Treated with Radiation Therapy

Cardiac diseases and cancers are leading causes of death [1]. Many cancer patients have preexistent cardiac impairment or have risk factors of developing it. On…

Time Optimisation in Radiation Therapy Planning: Insights from UK Surveys

Recently published data give a glimpse on the time spent for treatment preparation in UK radiation oncology centres. As expected,organ-at-risk and target contouring contouring is…

MVision AI receives TGA approval and market authorization for Australia

HELSINKI, Finland – May 1, 2024 An application for MVision AI Segmentation (Contour+) has been submitted and accepted by the Therapeutic Goods Administration (TGA) under…

Dharanipathy Rangaraj Appointed as CEO of MVision AI

Helsinki, Uusimaa – April 29, 2024 – MVision AI, a pioneering company in developing innovative AI solutions in the radiation oncology & imaging space, proudly…

MVision AI is delighted to announce that we have received our 2nd order for the Republic of Ireland from St. Luke’s Radiation Oncology Network (SLRON)

Finland, Helsinki, February 19, 2024 The contract for installing Contour+ Guideline Based AI Segmentation tool has been won through the public tender process and implies…

The world’s first comprehensive GBS™ solution for radiation therapy cancer treatment is now available for implementation in Canadian clinics

HELSINKI, Finland – January 22, 2024 MVision AI announces first Health Canada Medical Device License for MVision AI Segmentation (Contour+). In conjunction with Guide and…